BioSpace News Archive

BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that it has agreed to sell 2,500,000 shares of its common stock, $0.001 par value per share, in a “best efforts” underwritten offering for gross proceeds of $10 million.

Conformis, Inc. (NASDAQ:CFMS), a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture, and sell joint replacement implants and instruments that are individually sized and shaped, and which the company refers to as personalized or individualized, to fit each patient’s unique anatomy, announced today that management will present at the Cowen 40th Annual Health Care Conference in Boston.

SAN DIEGO, Feb. 21, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis” or the “Company”) today announced it has entered into a securities purchase agreement with certain accredited institutional investors to purchase approximately $6.7 million of its common stock in a registered direct offering and warrants to purchase shares of common stock in a concurrent private placement. The combined purchase price for one share of common stock and 0.75 warrants will be

The AKC Canine Health Foundation celebrates its 25th anniversary in 2020.

Feb. 21, 2020 15:13 UTC STAMFORD, Conn.--( BUSINESS WIRE )-- Purdue Pharma L.P. (“Purdue”) today announced the appointment of former United States Agriculture Secretary and Iowa Governor Tom Vilsack as Monitor under the voluntary self-injunction approved on November 6, 2019, in its chapter 11 bankruptcy case. In its initial bankruptcy filings, Purdue voluntarily proposed to formalize under court order its commitment to continue to refrain from engaging in certain promotional

The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 36 cents per share.

OSLO, Norway , Feb. 21, 2020 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANO) announces that it will report its results for the fourth quarter and full year 2019 on Thursday, 27 February 2020. A presentation by Nordic Nanovector’s senior management team will take place at 8:30am CET at: Thon Hotel Vika Atrium, Munkedamsveien 45, 0250 Oslo Meeting Room: VIPPETANGEN

Israel’s Sheba Medical Center, Tel HaShomer has confirmed the first case of coronavirus after 11 Israeli travelers from the Princess Diamond cruise ship were brought to an isolated unit at Sheba on Friday morning.

Dr. Scott Hacker announced today that he has treated his tenth patient in the ongoing Phase 3 clinical trial of NOVOCART 3D, an investigational autologous chondrocyte transplantation system designed to treat articular cartilage defects of the knee.

New high-performance chemistry combined with PCR-free DNBSEQ nanoarray platform delivers higher quality and more sequencing reads